Kesimpta, Kisqali, Cosentyx and Leqvio. The top line beat the Zacks Consensus Estimate of $12.97 billion. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. Shares are up in ...

Find the latest EPS estimates and surprises on Zacks Earnings Calendar. Novartis AG Price ... has likely fueled multiple sclerosis drug Kesimpta’s sales in the to-be-reported quarter.

Kesimpta is a brand-name subcutaneous injection prescribed for certain forms of multiple sclerosis (MS). Kesimpta begins working right away, but it may take some time for you to notice relief in ...

Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Kesimpta is such a drug, taken as an injection under the skin once a month. According to the MS Trust , it reduces the number of relapses by about two-thirds (70%). Safety, efficacy, and adherence ...

Apple’s ‘strategy’ with the Calendar app has always been a bit perplexing to me. The company knows that lots of iPhone users have been drawn away by alternative apps like Google Calendar ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

Increased demand has likely fueled multiple sclerosis drug Kesimpta’s sales in the to-be-reported quarter. The Zacks Consensus Estimate and our model estimate for Kesimpta's fourth-quarter sales ...